OT-62 TOPAS

DGAP-News: Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

Retrieved on: 
Thursday, July 29, 2021
Evotec, Armoured fighting vehicles, Boehringer Ingelheim, Health, Medicine, Topas, OT-62 TOPAS, Boehringer, Arthritis

Topas Therapeutics Extends Series B, Raising Total of 40 Million(~$ 48 Million) in this Round

Key Points: 
  • Topas Therapeutics Extends Series B, Raising Total of 40 Million(~$ 48 Million) in this Round
    The issuer is solely responsible for the content of this announcement.
  • The funding will be used to obtain clinical proof of concept in two programs and to accelerate the Company's proprietary pipeline based on the Topas Particle Conjugates technology platform.
  • Topas will also be advancing several of its pre-clinical-stage programs, including one for the treatment of rheumatoid arthritis and one for Type I diabetes.
  • Topas' investors are: BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III.

DGAP-News: Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

Retrieved on: 
Monday, October 19, 2020
Armoured fighting vehicles, Information technology management, Military vehicles, Topas, OT-62 TOPAS, OT, Top, Pemphigus vulgaris

Topas Therapeutics Appoints Klaus Martin, Ph.D. asChief Executive Officer

Key Points: 
  • Topas Therapeutics Appoints Klaus Martin, Ph.D. asChief Executive Officer
    The issuer is solely responsible for the content of this announcement.
  • Topas Therapeutics Appoints Klaus Martin, Ph.D. asChief Executive Officer
    Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform, with lead program TPM203 in clinical development for treatment of pemphigus vulgaris and second program, TPM501, progressing towards clinic for treatment of celiac disease
    Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer.
  • Erich F. Greiner, M.D., Chairman of the Supervisory Board, said: "We are delighted to have Klaus join Topas.
  • Klaus Martin, Ph.D., Chief Executive Officer, said: "Topas has a novel and compelling technology platform with the potential to develop promising treatments where new options for patients are urgently needed.

DGAP-News: Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

Retrieved on: 
Monday, October 19, 2020
Armoured fighting vehicles, Military vehicles, Topas, OT-62 TOPAS, Topas Therapeutics, BioMedPartners, Vesalius Biocapital III

New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors.

Key Points: 
  • New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors.
  • The funding will be used to advance the Company's proprietary pipeline based on the Topas Particle Conjugates technology platform.
  • Klaus Martin, Ph.D., Chief Executive Officer of Topas, said: "I am particularly gratified to begin my tenure at Topas with the completion of a successful financing round.
  • Dr. Greiner is CEO and President of Cedrus Therapeutics Inc. and has served on the Topas Supervisory Board since June 2016.